Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Apr 1;99(7):1682–1690. doi: 10.1172/JCI119331

Diversity and plasticity of self recognition during the development of multiple sclerosis.

V K Tuohy 1, M Yu 1, B Weinstock-Guttman 1, R P Kinkel 1
PMCID: PMC507988  PMID: 9120012

Abstract

Recent studies using murine animal model systems indicate that clinical progression of autoimmune disease may be due to the sequential accumulation of neoautoreactivity characterized by extensive plasticity of self recognition. In the present study, we addressed the question of whether a similar paradigm of self recognition is implicated in the development of multiple sclerosis (MS), a demyelinating disease with a presumed autoimmune etiology. Our approach was to determine serial changes over a 12-18-mo period in response to an epitope-mapping series of 265 12-mer peptides of myelin proteolipid protein (PLP) by patients with isolated monosymptomatic demyelinating syndromes (IMDS), a group of distinct clinical disorders with variable rates of progression to MS. Our data showed that an extensive array of proteolipid protein peptides could elicit autoreactivity. Moreover, differential autoreactive patterns were evident within IMDS patient subpopulations. Monocentric monophasic IMDS patients with no evidence of prior subclinical disease typically showed fully sustained autoreactivity characterized by extensive plasticity, epitope focusing, shifting, and spreading of responses to new self determinants. In contrast, multicentric monophasic IMDS patients with putative evidence of prior asymptomatic lesion formation typically showed partially sustained autoreactivity characterized by abrupt abrogation of responses to an extensive array of self determinants. No sustained autoreactivity was observed in normal control subjects or in patients with other neurologic diseases. Our results indicate that self recognition associated with the development of MS is a developmental process characterized by autoreactive diversity, plasticity, and instability.

Full Text

The Full Text of this article is available as a PDF (193.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allegretta M., Nicklas J. A., Sriram S., Albertini R. J. T cells responsive to myelin basic protein in patients with multiple sclerosis. Science. 1990 Feb 9;247(4943):718–721. doi: 10.1126/science.1689076. [DOI] [PubMed] [Google Scholar]
  2. Allen M., Sandberg-Wollheim M., Sjögren K., Erlich H. A., Petterson U., Gyllensten U. Association of susceptibility to multiple sclerosis in Sweden with HLA class II DRB1 and DQB1 alleles. Hum Immunol. 1994 Jan;39(1):41–48. doi: 10.1016/0198-8859(94)90099-x. [DOI] [PubMed] [Google Scholar]
  3. Baxevanis C. N., Reclos G. J., Servis C., Anastasopoulos E., Arsenis P., Katsiyiannis A., Matikas N., Lambris J. D., Papamichail M. Peptides of myelin basic protein stimulate T lymphocytes from patients with multiple sclerosis. J Neuroimmunol. 1989 Mar;22(1):23–30. doi: 10.1016/0165-5728(89)90005-2. [DOI] [PubMed] [Google Scholar]
  4. Beck R. W., Cleary P. A., Trobe J. D., Kaufman D. I., Kupersmith M. J., Paty D. W., Brown C. H. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med. 1993 Dec 9;329(24):1764–1769. doi: 10.1056/NEJM199312093292403. [DOI] [PubMed] [Google Scholar]
  5. Bhardwaj V., Kumar V., Grewal I. S., Dao T., Lehmann P. V., Geysen H. M., Sercarz E. E. T cell determinant structure of myelin basic protein in B10.PL, SJL/J, and their F1S. J Immunol. 1994 Apr 15;152(8):3711–3719. [PubMed] [Google Scholar]
  6. Brocke S., Gijbels K., Allegretta M., Ferber I., Piercy C., Blankenstein T., Martin R., Utz U., Karin N., Mitchell D. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature. 1996 Jan 25;379(6563):343–346. doi: 10.1038/379343a0. [DOI] [PubMed] [Google Scholar]
  7. Chou Y. K., Bourdette D. N., Offner H., Whitham R., Wang R. Y., Hashim G. A., Vandenbark A. A. Frequency of T cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis. J Neuroimmunol. 1992 May;38(1-2):105–113. doi: 10.1016/0165-5728(92)90095-3. [DOI] [PubMed] [Google Scholar]
  8. Clayton J. P., Gammon G. M., Ando D. G., Kono D. H., Hood L., Sercarz E. E. Peptide-specific prevention of experimental allergic encephalomyelitis. Neonatal tolerance induced to the dominant T cell determinant of myelin basic protein. J Exp Med. 1989 May 1;169(5):1681–1691. doi: 10.1084/jem.169.5.1681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Correale J., Gilmore W., McMillan M., Li S., McCarthy K., Le T., Weiner L. P. Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. J Immunol. 1995 Mar 15;154(6):2959–2968. [PubMed] [Google Scholar]
  10. Cross A. H., Tuohy V. K., Raine C. S. Development of reactivity to new myelin antigens during chronic relapsing autoimmune demyelination. Cell Immunol. 1993 Feb;146(2):261–269. doi: 10.1006/cimm.1993.1025. [DOI] [PubMed] [Google Scholar]
  11. FOLCH J., LEES M., SLOANE STANLEY G. H. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957 May;226(1):497–509. [PubMed] [Google Scholar]
  12. Filippi M., Horsfield M. A., Morrissey S. P., MacManus D. G., Rudge P., McDonald W. I., Miller D. H. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology. 1994 Apr;44(4):635–641. doi: 10.1212/wnl.44.4.635. [DOI] [PubMed] [Google Scholar]
  13. Franco A., Southwood S., Arrhenius T., Kuchroo V. K., Grey H. M., Sette A., Ishioka G. Y. T cell receptor antagonist peptides are highly effective inhibitors of experimental allergic encephalomyelitis. Eur J Immunol. 1994 Apr;24(4):940–946. doi: 10.1002/eji.1830240424. [DOI] [PubMed] [Google Scholar]
  14. Gammon G., Geysen H. M., Apple R. J., Pickett E., Palmer M., Ametani A., Sercarz E. E. T cell determinant structure: cores and determinant envelopes in three mouse major histocompatibility complex haplotypes. J Exp Med. 1991 Mar 1;173(3):609–617. doi: 10.1084/jem.173.3.609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Geysen H. M., Rodda S. J., Mason T. J., Tribbick G., Schoofs P. G. Strategies for epitope analysis using peptide synthesis. J Immunol Methods. 1987 Sep 24;102(2):259–274. doi: 10.1016/0022-1759(87)90085-8. [DOI] [PubMed] [Google Scholar]
  16. Kaufman D. L., Clare-Salzler M., Tian J., Forsthuber T., Ting G. S., Robinson P., Atkinson M. A., Sercarz E. E., Tobin A. J., Lehmann P. V. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature. 1993 Nov 4;366(6450):69–72. doi: 10.1038/366069a0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kennedy M. K., Tan L. J., Dal Canto M. C., Tuohy V. K., Lu Z. J., Trotter J. L., Miller S. D. Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides. J Immunol. 1990 Feb 1;144(3):909–915. [PubMed] [Google Scholar]
  18. Kerlero de Rosbo N., Milo R., Lees M. B., Burger D., Bernard C. C., Ben-Nun A. Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein. J Clin Invest. 1993 Dec;92(6):2602–2608. doi: 10.1172/JCI116875. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kuchroo V. K., Das M. P., Brown J. A., Ranger A. M., Zamvil S. S., Sobel R. A., Weiner H. L., Nabavi N., Glimcher L. H. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell. 1995 Mar 10;80(5):707–718. doi: 10.1016/0092-8674(95)90349-6. [DOI] [PubMed] [Google Scholar]
  20. Lehmann P. V., Forsthuber T., Miller A., Sercarz E. E. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature. 1992 Jul 9;358(6382):155–157. doi: 10.1038/358155a0. [DOI] [PubMed] [Google Scholar]
  21. Macklin W. B., Campagnoni C. W., Deininger P. L., Gardinier M. V. Structure and expression of the mouse myelin proteolipid protein gene. J Neurosci Res. 1987;18(3):383–394. doi: 10.1002/jnr.490180302. [DOI] [PubMed] [Google Scholar]
  22. Maeji N. J., Bray A. M., Geysen H. M. Multi-pin peptide synthesis strategy for T cell determinant analysis. J Immunol Methods. 1990 Nov 6;134(1):23–33. doi: 10.1016/0022-1759(90)90108-8. [DOI] [PubMed] [Google Scholar]
  23. Markovic-Plese S., Fukaura H., Zhang J., al-Sabbagh A., Southwood S., Sette A., Kuchroo V. K., Hafler D. A. T cell recognition of immunodominant and cryptic proteolipid protein epitopes in humans. J Immunol. 1995 Jul 15;155(2):982–992. [PubMed] [Google Scholar]
  24. Martin R., McFarland H. F., McFarlin D. E. Immunological aspects of demyelinating diseases. Annu Rev Immunol. 1992;10:153–187. doi: 10.1146/annurev.iy.10.040192.001101. [DOI] [PubMed] [Google Scholar]
  25. Martin R., Utz U., Coligan J. E., Richert J. R., Flerlage M., Robinson E., Stone R., Biddison W. E., McFarlin D. E., McFarland H. F. Diversity in fine specificity and T cell receptor usage of the human CD4+ cytotoxic T cell response specific for the immunodominant myelin basic protein peptide 87-106. J Immunol. 1992 Mar 1;148(5):1359–1366. [PubMed] [Google Scholar]
  26. McCarron R. M., Fallis R. J., McFarlin D. E. Alterations in T cell antigen specificity and class II restriction during the course of chronic relapsing experimental allergic encephalomyelitis. J Neuroimmunol. 1990 Sep-Oct;29(1-3):73–79. doi: 10.1016/0165-5728(90)90149-h. [DOI] [PubMed] [Google Scholar]
  27. McRae B. L., Vanderlugt C. L., Dal Canto M. C., Miller S. D. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med. 1995 Jul 1;182(1):75–85. doi: 10.1084/jem.182.1.75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Milner R. J., Lai C., Nave K. A., Lenoir D., Ogata J., Sutcliffe J. G. Nucleotide sequences of two mRNAs for rat brain myelin proteolipid protein. Cell. 1985 Oct;42(3):931–939. doi: 10.1016/0092-8674(85)90289-2. [DOI] [PubMed] [Google Scholar]
  29. Morrissey S. P., Miller D. H., Kendall B. E., Kingsley D. P., Kelly M. A., Francis D. A., MacManus D. G., McDonald W. I. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain. 1993 Feb;116(Pt 1):135–146. doi: 10.1093/brain/116.1.135. [DOI] [PubMed] [Google Scholar]
  30. Novotny J., Bruccoleri R. E., Carlson W. D., Handschumacher M., Haber E. Antigenicity of myohemerythrin. Science. 1987 Dec 11;238(4833):1584–1586. doi: 10.1126/science.2446393. [DOI] [PubMed] [Google Scholar]
  31. Ota K., Matsui M., Milford E. L., Mackin G. A., Weiner H. L., Hafler D. A. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature. 1990 Jul 12;346(6280):183–187. doi: 10.1038/346183a0. [DOI] [PubMed] [Google Scholar]
  32. Pelfrey C. M., Tranquill L. R., Boehme S. A., McFarland H. F., Lenardo M. J. Two mechanisms of antigen-specific apoptosis of myelin basic protein (MBP)-specific T lymphocytes derived from multiple sclerosis patients and normal individuals. J Immunol. 1995 Jun 1;154(11):6191–6202. [PubMed] [Google Scholar]
  33. Pelfrey C. M., Trotter J. L., Tranquill L. R., McFarland H. F. Identification of a novel T cell epitope of human proteolipid protein (residues 40-60) recognized by proliferative and cytolytic CD4+ T cells from multiple sclerosis patients. J Neuroimmunol. 1993 Jul;46(1-2):33–42. doi: 10.1016/0165-5728(93)90231-m. [DOI] [PubMed] [Google Scholar]
  34. Pelfrey C. M., Trotter J. L., Tranquill L. R., McFarland H. F. Identification of a second T cell epitope of human proteolipid protein (residues 89-106) recognized by proliferative and cytolytic CD4+ T cells from multiple sclerosis patients. J Neuroimmunol. 1994 Sep;53(2):153–161. doi: 10.1016/0165-5728(94)90025-6. [DOI] [PubMed] [Google Scholar]
  35. Perry L. L., Barzaga-Gilbert E., Trotter J. L. T cell sensitization to proteolipid protein in myelin basic protein-induced relapsing experimental allergic encephalomyelitis. J Neuroimmunol. 1991 Jul;33(1):7–15. doi: 10.1016/0165-5728(91)90029-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Pette M., Fujita K., Wilkinson D., Altmann D. M., Trowsdale J., Giegerich G., Hinkkanen A., Epplen J. T., Kappos L., Wekerle H. Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. Proc Natl Acad Sci U S A. 1990 Oct;87(20):7968–7972. doi: 10.1073/pnas.87.20.7968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Poser C. M., Paty D. W., Scheinberg L., McDonald W. I., Davis F. A., Ebers G. C., Johnson K. P., Sibley W. A., Silberberg D. H., Tourtellotte W. W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 Mar;13(3):227–231. doi: 10.1002/ana.410130302. [DOI] [PubMed] [Google Scholar]
  38. Richert J. R., Robinson E. D., Deibler G. E., Martenson R. E., Dragovic L. J., Kies M. W. Evidence for multiple human T cell recognition sites on myelin basic protein. J Neuroimmunol. 1989 Jun;23(1):55–66. doi: 10.1016/0165-5728(89)90073-8. [DOI] [PubMed] [Google Scholar]
  39. Rieckmann P., Albrecht M., Kitze B., Weber T., Tumani H., Broocks A., Lüer W., Helwig A., Poser S. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol. 1995 Jan;37(1):82–88. doi: 10.1002/ana.410370115. [DOI] [PubMed] [Google Scholar]
  40. Samson M. F., Smilek D. E. Reversal of acute experimental autoimmune encephalomyelitis and prevention of relapses by treatment with a myelin basic protein peptide analogue modified to form long-lived peptide-MHC complexes. J Immunol. 1995 Sep 1;155(5):2737–2746. [PubMed] [Google Scholar]
  41. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell. 1996 May 3;85(3):299–302. doi: 10.1016/s0092-8674(00)81107-1. [DOI] [PubMed] [Google Scholar]
  42. Sun J. B., Olsson T., Wang W. Z., Xiao B. G., Kostulas V., Fredrikson S., Ekre H. P., Link H. Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur J Immunol. 1991 Jun;21(6):1461–1468. doi: 10.1002/eji.1830210620. [DOI] [PubMed] [Google Scholar]
  43. Söderström M., Link H., Fredrikson S., Sun J. B. Optic neuritis and multiple sclerosis: the T cell repertoires to myelin proteins and MBP peptides change with time. Acta Neurol Scand. 1994 Jul;90(1):10–18. doi: 10.1111/j.1600-0404.1994.tb02673.x. [DOI] [PubMed] [Google Scholar]
  44. Tanaka H., Ota K., Ikusaka M., Ejima M., Maruyama S. [Expression of Fas-antigen on T cells in multiple sclerosis]. Rinsho Shinkeigaku. 1995 Mar;35(3):299–301. [PubMed] [Google Scholar]
  45. Trotter J. L., Hickey W. F., van der Veen R. C., Sulze L. Peripheral blood mononuclear cells from multiple sclerosis patients recognize myelin proteolipid protein and selected peptides. J Neuroimmunol. 1991 Jul;33(1):55–62. doi: 10.1016/0165-5728(91)90034-5. [DOI] [PubMed] [Google Scholar]
  46. Tuohy V. K., Lu Z., Sobel R. A., Laursen R. A., Lees M. B. Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice. J Immunol. 1989 Mar 1;142(5):1523–1527. [PubMed] [Google Scholar]
  47. Tuohy V. K. Peptide determinants of myelin proteolipid protein (PLP) in autoimmune demyelinating disease: a review. Neurochem Res. 1994 Aug;19(8):935–944. doi: 10.1007/BF00968703. [DOI] [PubMed] [Google Scholar]
  48. Yu M., Johnson J. M., Tuohy V. K. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease. J Exp Med. 1996 Apr 1;183(4):1777–1788. doi: 10.1084/jem.183.4.1777. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Zhang J., Vandevyver C., Stinissen P., Raus J. In vivo clonotypic regulation of human myelin basic protein-reactive T cells by T cell vaccination. J Immunol. 1995 Dec 15;155(12):5868–5877. [PubMed] [Google Scholar]
  50. Zhang Y., Burger D., Saruhan G., Jeannet M., Steck A. J. The T-lymphocyte response against myelin-associated glycoprotein and myelin basic protein in patients with multiple sclerosis. Neurology. 1993 Feb;43(2):403–407. doi: 10.1212/wnl.43.2.403. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES